Abstract:e21043 Background: Molecular testing is mandatory in advanced non-small cell lung cancer (NSCLC) due to prognostic and therapeutic implications. Correlation between blood and tissue next-generation sequencing (NGS) has recently been demonstrated. Methods: A retrospective observational study of two cohorts of NSCLC patients who underwent liquid biopsy at the time of advanced disease diagnosis was conducted. In cohort 1 (N = 129), liquid biopsy was performed using a 74 genes panel (Guardant360 CDx). In cohort 2 (N = 149), NGS was performed in peripheral blood using a 63 genes panel (FoundationOne Liquid CDx). For tissue NGS analysis, Oncomine Precision Assay and Oncomine Focus Assay, with 50 and 52 genes, respectively, were performed. Data were analyzed in both cohorts independently, and compared by statistical descriptive methods. Results: In cohort 1, 74/129 (57.4%) were men and 55/129 (42.6%) were non-smokers or had a ≤ 20-pack-year tobacco history. The most frequent histology was adenocarcinoma (99/129; 76.7%). In 14/129 (10.9%) patients, a second determination of NGS in peripheral blood was necessary and 1/129 (0.8%) had a total of three determinations. Tissue NGS was not performed in 32/129 (24.8%) because of insufficient sample. In cohort 2, 99/149 (66.4%) were men and 48/149 (32.2%) were non-smokers or had a ≤ 20-pack-year tobacco history. The most frequent histology was adenocarcinoma (99/149; 66.4%). Tissue NGS was not performed in 40/149 (26.8%) due to insufficient sample (26/40; 65%) or technical difficulties to perform a biopsy (14/40; 35%). In cohort 1, pathogenic mutations were detected in 119/129 (92.2%) and in 62/97 (63.9%) patients (p < 0.001), with median time to obtain results of 11 (IQR 9-14) and 29 (IQR 22-39) days for blood and tissue NGS, respectively (p < 0.001). Actionable mutations included alterations of levels I-II according to ESCAT and were found in 40/129 (31%) and 33/97 (34%) patients using blood and tissue NGS, respectively (p = 0.63). In cohort 2, circulating tumor DNA was not detected in 5/149 (3.5%) patients. Pathogenic mutations were found in 123/149 (82.6%) and in 71/109 (65.1%) patients (p = 0.001), with median time to obtain results of 15 (IQR 14-15) and 27 (IQR 16-27) days for blood and tissue NGS, respectively (p < 0.001). Actionable mutations were detected in 41/149 (27.5%) and 41/109 (37.6%) using blood and tissue NGS, respectively (p = 0.08). Targeted therapy was given to 31/129 (24%) and 39/149 (26.2%) patients in cohort 1 and 2, respectively. Conclusions: To our knowledge, this is the first retrospective observational study where liquid biopsy and tissue NGS are compared in two different cohorts of patients with advanced NSCLC. Time to obtain results was shorter for blood NGS than tissue sequencing, and liquid biopsy provided molecular information in cases in which tissue NGS is not available. Further studies to identify patients in which liquid biopsy could replace tissue analysis are needed.

Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain

Comparison between liquid biopsy and tissue NGS in two cohorts of advanced NSCLC.

Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study

Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Abstract 6132: Exploring genomic complexity in lung cancer at the Tijuana/California border: A real-world perspective through liquid biopsy comprehensive genomic profiling

Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Results of the First In Situ Implementation of Comprehensive Genomic Profiling

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls